Alpha 2.0
Login Register
» Authors » Andreas Hallqvist

Andreas Hallqvist

Explore the profile of Andreas Hallqvist including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 307
Followers 0
Related Specialties
Oncology
Radiology
Nuclear Medicine
Top 10 Co-Authors
Jan Nyman
Per Albertsson
Volkan I Sayin
Stig Palm
Johanna Svensson
Sukanya Raghavan
Tom Back
Peter Bernhardt
Levent M Akyurek
Sture Lindegren
Published In
Radiother Oncol
J Nucl Med
Acta Oncol
Front Oncol
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
Hallqvist A, Brynjarsdottir E, Krantz T, Sjogren M, Svensson J, Bernhardt P
J Nucl Med . 2025 Feb; PMID: 40015919
This phase I trial aimed to assess the feasibility and toxicity of combining the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib with Lu-DOTATATE in patients with somatostatin receptor-positive tumors, with the goal...
2.
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer
Eklund E, Svensson J, Naslund L, Yhr M, Sayin S, Wiel C, et al.
J Exp Clin Cancer Res . 2025 Feb; 44(1):75. PMID: 40011914
Background: In non-small cell lung cancer (NSCLC), the rapid advancement of predictive genetic testing of tumors by identifying specific pathogenic driver variants has significantly improved treatment guidance. However, immune checkpoint...
3.
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
Persson A, Hallqvist A, Bjorn Larsen L, Rasmussen M, Scherman J, Nilsson P, et al.
Radiat Oncol . 2024 Dec; 19(1):173. PMID: 39690404
Background: The use of stereotactic body radiotherapy (SBRT) to definitively treat oligometastases in prostate cancer has drawn large clinical and research interests within radiation oncology. However, the evidence is considered...
4.
Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
Gunnarsson K, Movik L, Pettersson N, Back A, Nyman J, Hallqvist A
Acta Oncol . 2024 Oct; 63:791-797. PMID: 39415565
Purpose: Radiation pneumonitis (RP) is a dose-limiting toxicity associated with increased mortality for patients with non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT). This study aims to assess the...
5.
Assessing the prognostic value of mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis
Eklund E, Mourad A, Wiel C, Sayin S, Fagman H, Hallqvist A, et al.
Front Oncol . 2024 Jun; 14:1396285. PMID: 38884086
Background: mutation status is a well-established independent prognostic factor in advanced non-small cell lung cancer (NSCLC), yet its role in early-stage disease is unclear. Here, we investigate the prognostic value...
6.
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less and More Mutations Compared to Advanced Adenocarcinomas
Petterson J, Mustafa D, Bandaru S, Eklund E, Hallqvist A, Sayin V, et al.
Int J Mol Sci . 2024 Mar; 25(5). PMID: 38474205
Pulmonary adenocarcinoma (ADC) is a very diverse disease, both genetically and histologically, which displays extensive intratumor heterogeneity with numerous acquired mutations. ADC is the most common type of lung cancer...
7.
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
Sundstrom P, Dutta N, Rodin W, Hallqvist A, Raghavan S, Quiding Jarbrink M
Oncoimmunology . 2024 Feb; 13(1):2312631. PMID: 38343750
Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions...
8.
KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry
Isaksson J, Berglund A, Louie K, Willen L, Hamidian A, Edsjo A, et al.
Clin Lung Cancer . 2023 Jun; 24(6):507-518. PMID: 37296038
Background: Real-world data on demographics related to KRAS mutation subtypes are crucial as targeted drugs against the p.G12C variant have been approved. Method: We identified 6183 NSCLC patients with reported...
9.
Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [Lu]Lu-DOTATATE Treatment
Hemmingsson J, Svensson J, Hallqvist A, Smits K, Johanson V, Bernhardt P
J Nucl Med . 2023 Jun; 64(9):1456-1462. PMID: 37290797
Bone marrow suppression is a common side effect after [Lu]Lu-DOTATATE treatment of neuroendocrine neoplasms. Neuroendocrine neoplasms share expression of somatostatin receptor type 2 with CD34-positive hematopoietic progenitor cells, potentially leading...
10.
Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer
Dutta N, Rohlin A, Eklund E, Magnusson M, Nilsson F, Akyurek L, et al.
Front Oncol . 2023 Feb; 12:1073457. PMID: 36844924
Objectives: Immunotherapy by blocking programmed death protein-1 (PD-1) or programmed death protein-ligand1 (PD-L1) with antibodies (PD-1 blockade) has revolutionized treatment options for patients with non-small cell lung cancer (NSCLC). However,...